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Rose Said1,2†, Véronique Regnault1,2†, Marie Hacquard1,3, Jean-Pierre Carteaux1 and Thomas Lecompte1,2,3,4*Abstract
Background: Bleeding remains a potentially lethal complication of cardio-pulmonary bypass (CPB) surgery. The
purpose of this study was to obtain a better insight into in vitro thrombin generation in the context of CPB.
Methods: We used Calibrated Automated Thrombography to assess blood coagulation of 10 low-risk patients
operated for valve replacement with CPB, under 2 experimental conditions, one implicating platelets as platelet
dysfunction has been described to occur during CPB.
Results: Our main finding was that CPB-induced coagulopathy was differently appreciated depending on the
presence or absence of platelets: the decrease in thrombin generation was much less pronounced in their presence
(mean endogenous thrombin potential change values before and after CPB were -3.9% in the presence of platelets
and -39.6% in their absence).
Conclusion: Our results show that experimental conditions have a profound effect in the study of in vitro thrombin
generation in the context of CPB.
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Bleeding remains a feared complication of cardiopul-
monary bypass (CPB) surgery. Despite improvements,
blood coagulation is still altered in the extracorporeal
circuit [1-4]. We have reported in variant haemophiliacs
that Calibrated Automated Thrombography (CAT), as
an integrative in vitro phenotyping of coagulation, would
be a better laboratory approach to assess the bleeding
risk than the assays currently used in laboratory medi-
cine [5]. Recent works have studied CAT thrombin gen-
eration in plasma of patients after CPB. Schols et al. [6]
showed a decrease in thrombin generation associated
with a decrease in fibrin formation (assessed with
thromboelastography). In addition, Solomon et al [7]* Correspondence: ThomasPierre.Lecompte@hcuge.ch
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reproduction in any medium, provided the orhave shown that fibrin formation is more altered than
thrombin generation following CPB. Furthermore,
Coakley et al. [8] have shown a correlation between pre-
and post-operative Endogenous Thrombin Potentials
(ETP), and more importantly an association with bleed-
ing complications, suggesting that this assay is inform-
ative in this context [5]. CAT can be performed in the
presence of platelets [9]. To obtain a better insight into
in vitro thrombin generation in the context of CPB, we
used CAT under 2 experimental conditions, one impli-
cating platelets. To the best of our knowledge this has
never been performed with CAT in the context of CPB.Materials and methods
Patient population
Ten low-risk adult patients scheduled for replacement of
one heart valve (6 aortic, 4 mitral) included. There were
7 men and 3 women; 70 years (59-87) of age (continuous
variables are expressed as medians and ranges). All. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients’ coagulation parameters before and
after surgery
Pre-operatively Post-operatively
Platelet count (G/L) 240 (109-337) 122 (67-201)
prothrombin time (sec) 12.9 (12.9-13.9) 16.5 (14.8-19.7)
aPTT (sec) 33 (29-59) 43 (34-58)
Fibrinogen (g/L) 4 (3.4-4.6) 2.3 (1.3-2.7)
Prothrombin (%) 85.5 (55-95) 57.5 (30-73)
Antithrombin (%) 97.5 (70-108) 64 (44-77)
Data are reported as median (min-max) of 10 patients. All decreases in platelet
count, prothrombin time, aPTT, fibrinogen, prothrombin and antithrombin are
statistically significant. p< 0.05 when comparing post-operating parameter to
pre-operating parameter. CPB: cardiopulmonary bypass, aPTT: activated partial
thromboplastin time.
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the local research committee.
Collection of blood samples
Venous blood samples were collected before CPB and
shortly after protamine injection into S-MonovetteW
tubes (Sarstedt) containing 0.109 M citrate, in the propor-
tion of 1 volume citrate to 9 volumes of blood. Platelet-
Rich Plasma (PRP) was prepared by blood centrifugation
at 190 g for 10 min at 20°C. The PRP was recovered and
adjusted to 150 G/L by the addition of Platelet-Poor
Plasma (PPP) obtained by centrifugation of the remaining
blood at 1750 g for 10 min at 20°C. Platelet- depleted
Plasma (PDP) was obtained from PPP centrifuged at
13000 g for 30 min at 4°C. PDP was immediately frozen at
-80°C and thawed 15 min at 37°C when needed.
Thrombin generation
CAT was performed with PRP and PDP as well, as
described in [10]. Measurements were carried out in 96-
well circular bottom microtiter polypropylene plates
(Greiner). Coagulation was initiated with 0.3 (PRP and
PDP), 1 or 5 pM (PDP only, for practical reasons) re-
combinant human tissue factor (TF) reagent (InnovinW,
Dade Behring), and, when PDP was studied, in the pres-
ence of 4 μM phospholipid vesicles: phosphatidylcholine
(PC)/ phosphatidylserine (PS)/ phosphatidylethanola-
mine (PE); (PC/PS/PE, 60/20/20, mole %).
Statistical analysis
Data are presented as median (min-max). Wilcoxon test
was used to compare before and after surgery coagula-
tion parameters (platelet count, prothrombin time, acti-
vated partial thromboplastin time (aPTT), fibrinogen,
antithrombin, and prothrombin) as well as the decrease
in ETP (before /after CBP) with both PRP and PDP at
different TF concentrations. ETP values obtained by the
different preparations were compared using a Kruskall-
Wallis test both before and after surgery.
Results
Surgery was uneventful as indicated by the following
parameters: CPB duration (min): 64 (48-118); cross
clamp time (min): 52 (25-90); 24 h blood loss (mL): 385
(170-750). Coagulation parameters measured before and
after surgery are shown in Table 1.
Heparin neutralization with protamine was checked
with thrombin time. No patient was transfused before
blood sampling. Tranexamic acid was routinely used. No
patient was transfused before the second blood sampling.
Thrombin generation was studied in vitro by CAT
using citrated plasma in presence or absence of platelets.
As expected from the design of our study, no patient
had abnormal bleeding, the maximal volume collectedduring the first 24 hours being 750 mL, and the lowest
post-CPB ETP we observed, was greater than 1000 nM.
min (with PRP).
Comparison of ETP from different experimental con-
ditions by Kruskall-Wallis test did not show any signifi-
cant difference before surgery (p = 0.0674). However
after surgery ETP values were significantly different
among preparations (p = 0.0009). Therefore we chose to
compare ETP values before and after surgery for each
preparation separately.
There was a statistically significant (Wilcoxon test) de-
crease in ETP (before /after CBP) with both PRP and
PDP regardless the TF concentration. Our main finding
was that CPB-induced coagulopathy was differently
appreciated depending on the presence or absence of
platelets. The percentage of variation between pre- and
post-operative values of ETP was much lower with PRP
(-3.9%) than with PDP (-39.6%) compared with a statis-
tical Wilcoxon test (Table 2).
The ETP pre-post variations observed with PRP were
statistically significantly different compared to PDP in
the presence of 0.3 pM TF, but not to PDP in the pres-
ence of 1 and 5 pM, probably because of a greater varia-
tions between the individual values. In our hands, 0.3
pM is the lowest TF concentration allowing reliable ob-
servation of thrombin generation and fully taking into
account the ‘intrinsic’ tenase (anti-haemophilic factors).Discussion
Our results show that coagulopathy associated to CPB
was observed, in vitro, not only with PPP but also with
PRP. Our main new observation is that this coagulopa-
thy was differently appreciated depending on the pres-
ence or absence of platelets.
The number of enrolled subjects (10 patients recruited
in this study) was estimated to allow us to document the
actual extent of hypocoagulability and to compare the
different experimental settings.
Table 2 Thrombin generation before and after CPB with PRP and PDP (at three TF concentrations)
ETP (nM.min)
Pre-operatively Post-operatively Change (%)
PRP (0.3 pM TF) 1505 (1160-2464) 1491 (1087-2544) -3.9 (4; -26.1)
PDP (0.3 pM TF) 1468 (1032-1913) 970 (500-1323) -39.6 (13.9; -61.3)
PDP (1 pM TF) 1560 (1255-1928) 1083 (742-1990) -24.4 (18.7; -52.7)
PDP (5 pM TF) 1723 (1338-2121) 1189 (810-2335) -30,5 (28; -52.7)
Data are reported as median (min-max) of at least 8 patients (10 patients enrolled- a few missing data for technical reasons). All decreases in ETP are statistically
significant. p< 0.05 when comparing ETP change with PRP to those with PDP in presence of 0.3 pM TF. ETP: Endogenous Thrombin Potential. PDP: platelet-depleted
plasma, PRP: platelet-rich plasma, TF: recombinant human tissue factor.
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The lowest post-CPB ETP we observed, was greater than
1000 nM.min (with PRP); in one of our previous works
[5], we reported the normal ETP to be 1579 ± 359 nM.
min and for mild heamophiliacs the average value was
1060 ± 450 nM.min.
Our results concerning the decrease in ETP values
with PDP after CPB were in agreement with previous
studies [7,8] studied only with PPP and in presence of
very higher TF concentration (20 pM) used in [7]. This
suggests that the observed coagulopathy after CPB was
not associated with the amplification phase of thrombin
generation which depends on the TF concentration and
is rather associated with the global phenomenon of
thrombin generation.
Moreover, we did not find any consistent change in
the duration of the initiation phase (by contrast to what
has been reported in [8] “data not shown”). In addition,
we have shown that this decrease in ETP values occurs
also with PRP after CPB. Several mechanisms have been
implicated in the haemostatic defects observed after
CPB: consumption of coagulation factors and platelets,
dilution, activation of fibrinolysis and transient platelet
function defect [2,11-15].
Although we have not studied platelet function in the
PRP of our patients, many other studies have described
that platelet dysfunction is thought to result from many
factors, such as contact with the synthetic surfaces of
the extracorporeal circuit and hypothermia associated
with bypass [2,11,12]. Many alterations have been
reported, including ? granule depletion and membrane
glycoprotein decreases such as GPIIbIIIa [2,11,12]. No
major alteration of procoagulant properties of platelets
has been reported however, which is consistent with the
slight decrease in ETP we observed with patients’ PRP.
This explanation is supported by the observation of Re-
verter et al. [16] that a platelet dysfunction in patients of
Glanzmann syndrome who lack GP IIb/IIIa on platelet
surfaces results in a moderate impact on thrombin gen-
eration (21% less than normal platelets). They have also
shown a moderate deficiency in thrombin generation
(25%) in the presence of antibodies against GPIIbIIIa.
Although this effect has not been described directly inthe context of CPB, a significant decrease in the amount
of membrane antigen for glycoproteins as IIb, and IIIa
on circulating platelets following CPB has been reported
[2]). In addition, the depletion of ? granules, which con-
tain GPIIbIIIa, has been reported in the context of CPB
[2,12]. In addition, we suggest that other procoagulant
actors would be present in PRP and not in PDP, capable
of compensating plasma coagulopathy. This hypothesis
is supported by the finding that procoagulant micropar-
ticles are generated during CPB, released not only from
platelets but also from erythrocytes, monocytes, granulo-
cytes and other cells, especially into pericardial blood
[17]. Thus, these microparticles, eliminated with the
centrifugation used to prepare PDP, might play, in vitro,
a procoagulant role in coagulation with PRP, but not
with PDP. Whatever the reason, it appears that a plasma
hemostatic defect can be partly compensated by platelets
[18]. However, the relation between these measure-
ments, in vitro, and the clotting process, in vivo, is
unknown.
In conclusion, our findings highlight that the experi-
mental conditions are crucial in the study of in vitro
thrombin generation in the context of CPB, the presence
of platelets and microparticles being associated with a
distinct pattern.
Limitations of this study
Other experimental conditions for CAT had to be taken
into account, for example, platelet count, the use of corn
trypsin inhibitor (CTI) – to prevent artificial contact
phase activation –, the concentration of TF; and the
activated protein C system which would improve the re-
lation to clinical outcome.
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